

CSD/BSE&NSE/GEN/2022-23
August 9, 2022

To
The Manager
Department of Corporate Services
BSE Limited
25th Floor, P. J. Towers,
Dalal Street, Mumbai - 400 001

To
The Manager
Listing Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex
Bandra (E), Mumbai – 400 051

Scrip Code: 543064

Scrip Symbol: SUVENPHAR

Dear Sir/Madam,

Sub: General Update

.....

With reference to the above subject, the Board of Directors of the company, at its meeting held on August 08, 2022, took note of the letter reference No. SOP-Review-(20-May-2022) received from BSE and NSE/LIST-SOP/COMB/FINES/0823, dated May 20, 2022 received from NSE in the matter of non-compliance identified with respect to Regulation 19 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and given below comments:

The Board has taken on record the letters received from stock exchanges conveying non-compliance of composition of NRC for the quarter ended 31st March, 2022 and also the penalty levied and paid by the Company. The Board has advised the management of the company to exercise more care in ensuring conformances to the LODR Regulations. The Board also advised to seek external opinion in case of ambiguity in proper interpretation of the Regulations.

This is for your information and record.

Thanking you,
Yours faithfully,
For **Suven Pharmaceuticals Limited**



K Hanumantha Rao
Company Secretary

Suven Pharmaceuticals Limited